Respiratory Signs and Symptoms DRG | Inpatient Reimbursement

Summary & Overview

Respiratory Signs and Symptoms: Inpatient Reimbursement Overview

DRG 204 encompasses hospital stays for acute respiratory signs and symptoms without a definitive primary respiratory disease diagnosis, focusing on evaluation and short-term respiratory support. Understanding this Diagnosis-Related Group is important for inpatient reimbursement because coding specificity and documented resource use determine Medicare payment and case-mix classification.

Respiratory Signs and SymptomsDRG Respiratory Signs and SymptomsDRG 204Diagnosis-Related GroupInpatient ReimbursementMedicarePulmonologyEmergency MedicineHospital Medicine

DRG 204 Overview

DRG 204 covers admissions with primary presentations of respiratory signs and symptoms, such as dyspnea, cough, hypoxemia, or respiratory distress, when a specific organ system diagnosis is not the principal coded condition. This Diagnosis-Related Group captures a heterogeneous clinical population that often requires diagnostic evaluation, oxygen therapy, and short-term respiratory support. It matters for Medicare payment because relative resource use for workup and monitoring drives reimbursement assignment and hospital billing complexity. Accurate principal diagnosis coding influences classification into this Diagnosis-Related Group and thus affects inpatient payment.

National Payment Rates

Across payers the observed payment range runs from about $7.3K to $23K, with the widest spread between the lowest and highest payer medians being roughly $16K. See the table and chart below for payer-level percentile breakout and distribution. Payer labels in the benchmarks correspond to Blue Cross Blue Shield, Cigna, Aetna, and Anthem.

Mean Rates by Payer — National — DRG 204

The CMS 2023 data represent national Medicare fee-for-service inpatient payments as reported under the CMS Provider Utilization and Payment Data program. The table below shows average total payment, average submitted covered charges, average Medicare payment amount, and total discharges for DRG 204. These figures summarize payments and utilization for Medicare FFS beneficiaries only.

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

For DRG 204, payer mean rates in Alaska range from 13K to 19K across the three reported payers, reflecting a moderate spread in reimbursement. Cigna stands out at the high end with a mean of 19K while Anthem and Blue Cross Blue Shield are clustered at 13K. This represents a notable upward deviation for Cigna relative to national averages. See the table and chart below for detailed distributions by payer.

Key Insights for Alaska

Cigna is the highest-paying payer in Alaska with a mean of 19K, while Anthem and Blue Cross Blue Shield are tied as the lowest-paying payers at 13K.
Alaska’s mean rates skew higher than national means for some payers (Cigna’s 19K vs national Cigna mean ~13K), indicating a meaningful upward deviation for that payer.

Clinical Trials

Acute diagnostic and early intervention studies: trials that evaluate rapid diagnostic strategies (e.g., point-of-care imaging algorithms, bundled lab panels, or novel biomarkers) and immediate management pathways for patients admitted with undifferentiated respiratory signs and symptoms such as dyspnea, hypoxia, or acute cough. These studies typically enroll adults presenting to emergency departments or hospital observation units to determine which diagnostic approach most efficiently identifies underlying etiologies (e.g., heart failure, COPD exacerbation, pneumonia, pulmonary embolism) and guides early treatment decisions. Results are relevant to providers and payers because faster, more accurate diagnosis can reduce unnecessary admissions, shorten length of stay, and target resource use during the highest-cost phase of care for this DRG.
Comparative effectiveness trials of inpatient management strategies: randomized or pragmatic trials comparing treatment pathways for common inpatient respiratory syndromes grouped under this DRG, such as protocolized oxygen and noninvasive ventilation strategies, antibiotic stewardship approaches for suspected infectious causes, or early mobilization and respiratory therapy bundles for hypoxemic patients. These studies enroll hospitalized patients with respiratory signs and symptoms after initial stabilization and address which standard-of-care variations lead to better in-hospital outcomes (e.g., need for ICU transfer, duration of oxygen therapy, complications). Findings inform clinicians and payers about which care processes improve outcomes and value, supporting adoption of practices that reduce complications and downstream costs associated with prolonged or escalated care.
Post-discharge outcomes and care-transition studies: observational cohorts and interventional trials focusing on readmission prevention, outpatient follow-up strategies, and patient-centered outcomes for individuals discharged after an admission coded to this DRG. Research targets patients at risk of recurrent respiratory events—such as those with prior COPD, heart failure, or recurrent pneumonia—and tests interventions like structured discharge education, early outpatient clinic contact, remote monitoring of oxygenation/symptoms, or home-based pulmonary rehabilitation referrals. This research is critical for payers and providers because it addresses drivers of 30-day readmissions, post-acute utilization, and long-term functional status, informing programs that can lower avoidable rehospitalizations and total cost of care.

Related Codes

201-PNEUMOTHORAX-WITHOUT-CC-MCC

Pneumothorax without CC/MCC: Inpatient Reimbursement Overview

185-MAJOR-CHEST-TRAUMA-WITHOUT-CC-MCC

Major Chest Trauma without CC/MCC: Inpatient Reimbursement Overview

165-MAJOR-CHEST-PROCEDURES-WITHOUT-CC-MCC

Major Chest Procedures without CC/MCC: Inpatient Reimbursement Overview

202-BRONCHITIS-AND-ASTHMA-WITH-CC-MCC

Bronchitis and Asthma with CC/MCC: Inpatient Reimbursement Overview

163-MAJOR-CHEST-PROCEDURES-WITH-MCC

Major Chest Procedures with MCC: Inpatient Reimbursement Overview

183-MAJOR-CHEST-TRAUMA-WITH-MCC

Major Chest Trauma with MCC: Inpatient Reimbursement Overview

179-RESPIRATORY-INFECTIONS-AND-INFLAMMATIONS-WITHOUT-CC-MCC

Respiratory Infections and Inflammations without CC/MCC: Inpatient Reimbursement Overview

168-OTHER-RESPIRATORY-SYSTEM-O-R-PROCEDURES-WITHOUT-CC-MCC

Other Respiratory System O.R. Procedures without CC/MCC: Inpatient Reimbursement Overview

177-RESPIRATORY-INFECTIONS-AND-INFLAMMATIONS-WITH-MCC

Respiratory Infections and Inflammations with MCC: Inpatient Reimbursement Overview

197-INTERSTITIAL-LUNG-DISEASE-WITH-CC

Interstitial Lung Disease with CC: Inpatient Reimbursement Overview

Showing 1–10 of 40

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$7.8K	$42K	$5.9K	4.4K

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Mean Rates by Payer — Alaska — DRG 204

Key Insights for Alaska

Cigna is the highest-paying payer in Alaska with a mean of 19K, while Anthem and Blue Cross Blue Shield are tied as the lowest-paying payers at 13K.
Alaska’s mean rates skew higher than national means for some payers (Cigna’s 19K vs national Cigna mean ~13K), indicating a meaningful upward deviation for that payer.

Clinical Trials

Acute diagnostic and early intervention studies: trials that evaluate rapid diagnostic strategies (e.g., point-of-care imaging algorithms, bundled lab panels, or novel biomarkers) and immediate management pathways for patients admitted with undifferentiated respiratory signs and symptoms such as dyspnea, hypoxia, or acute cough. These studies typically enroll adults presenting to emergency departments or hospital observation units to determine which diagnostic approach most efficiently identifies underlying etiologies (e.g., heart failure, COPD exacerbation, pneumonia, pulmonary embolism) and guides early treatment decisions. Results are relevant to providers and payers because faster, more accurate diagnosis can reduce unnecessary admissions, shorten length of stay, and target resource use during the highest-cost phase of care for this DRG.
Comparative effectiveness trials of inpatient management strategies: randomized or pragmatic trials comparing treatment pathways for common inpatient respiratory syndromes grouped under this DRG, such as protocolized oxygen and noninvasive ventilation strategies, antibiotic stewardship approaches for suspected infectious causes, or early mobilization and respiratory therapy bundles for hypoxemic patients. These studies enroll hospitalized patients with respiratory signs and symptoms after initial stabilization and address which standard-of-care variations lead to better in-hospital outcomes (e.g., need for ICU transfer, duration of oxygen therapy, complications). Findings inform clinicians and payers about which care processes improve outcomes and value, supporting adoption of practices that reduce complications and downstream costs associated with prolonged or escalated care.
Post-discharge outcomes and care-transition studies: observational cohorts and interventional trials focusing on readmission prevention, outpatient follow-up strategies, and patient-centered outcomes for individuals discharged after an admission coded to this DRG. Research targets patients at risk of recurrent respiratory events—such as those with prior COPD, heart failure, or recurrent pneumonia—and tests interventions like structured discharge education, early outpatient clinic contact, remote monitoring of oxygenation/symptoms, or home-based pulmonary rehabilitation referrals. This research is critical for payers and providers because it addresses drivers of 30-day readmissions, post-acute utilization, and long-term functional status, informing programs that can lower avoidable rehospitalizations and total cost of care.